TITLE

Thalidomide and cancer cachexia: old problem, new hope?

AUTHOR(S)
Stroud, M.
PUB. DATE
April 2005
SOURCE
Gut;Apr2005, Vol. 54 Issue 4, p447
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
This article focuses on role of thalidomide in weight loss in patients with advanced pancreatic cancer. The cancer cachexia syndrome is common. Significant weight loss occurs in approximately 50% of oncology patients, with even higher values in those with gastrointestinal tumors. In pancreatic cancer, approximately 80% of patients will become severely malnourished. Greater comprehension of the mechanisms underlying cancer cachexia has come from examination of the systems that regulate cellular metabolism.
ACCESSION #
16556642

 

Related Articles

  • Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma. Boyar, Michelle S.; Hesdorffer, Mary; Keohan, Mary Louise; Zhezhen Jin; Taub, Robert N. // Sarcoma;2008, p1 

    We assessed the efficacy of combined temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma in a Phase II single-institution trial. Twenty-four patients were enrolled. Temozolomide (150 mg/m2/day for 7 days every other week) was administered with concomitant...

  • Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma. Ribatti, Domenico; Vacca, Angelo // Letters in Drug Design & Discovery;Apr2004, Vol. 1 Issue 2, p135 

    Experimental studies have demonstrated that thalidomide, a drug developed as a sedative, has antitumoral properties. Its broad spectrum of actions besides its antiangiogenic potential, includes immunomodulatory properties, antiinflammatory actions and direct effect on tumor cells and their...

  • Thalidomide.  // Reactions Weekly;4/24/2004, Issue 998, p16 

    Presents information on a study on the occurrence of atrial thrombosis in the course of multiple myeloma treated with thalidomide, by F. Barbou et al., published in the October 2003 issue of the "Archives des Maladies du Coeur et des Vaisseaux" journal.

  • Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Ribatti, D.; Vacca, A. // Leukemia (08876924);Sep2005, Vol. 19 Issue 9, p1525 

    Very few drugs had a history similar to that of thalidomide (α-N-[phthalimido] gluramide). First introduced in the late 1950s in Germany, in 1961 thalidomide was withdrawn due to its teratogenic effects. More than three decades after, it is attracting growing interest because of its reported...

  • Effects of Some Natural Immunomodulatory Compounds in Combination with Thalidomide on Survival Rate and Tumor Size in Fibrosarcoma-Bearing Mice. Maleki, Reza Aghebati; Shanehbandi, Dariush; Eteghad, Saeed Sadigh; Zarredar, Habib; Shahneh, Fatemeh Zare; Maleki, Leili Aghebati; Samavati, Mehrnosh; Asadi, Hamed; Mosavi, Seyed Ehsan; Habibzadeh, Afshin; Mohammadian, Mozhdeh; Baradaran, Behzad // Advanced Pharmaceutical Bulletin;2014 Supplement 1, Vol. 4, p465 

    Purpose: Despite significant advances have been achieved in cancer therapy, response to conventional treatments like surgery, radiotherapy and chemotherapy varies among individuals. Immunotherapy is known to be an effective strategy for patients who are resistant to the currently available...

  • Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma. Das, Anupam; Sil, Amrita; Mishra, Vivek; Kanti Das, Nilay // Indian Journal of Pharmacology;Sep/Oct2014, Vol. 46 Issue 5, p557 

    Thalidomide developed in 1954 for morning sickness had proven to be a teratogen and hence was withdrawn from market. Resurgence of thalidomide began as an immunomodulator when it was shown to be effective in the management of multiple myeloma and many conditions like erythema nodosum leprosum,...

  • Despite Checkered Past, Thalidomide and Its Analogues Show Potential. Friedrich, M.J. // JNCI: Journal of the National Cancer Institute;9/4/2002, Vol. 94 Issue 17, p1270 

    Examines the therapeutic use of thalidomide. Antiangiogenic properties; Toxicities; Analogues; New indications for thalidomide; Possible side effects of thalidomide.

  • Intraductal Papillary-Mucinous Tumor of the Pancreas: Assessing the Grade of Malignancy from Natural History. Yamaguchi, Koji; Sugitani, Atsushi; Chijiiwa, Kazuo; Tanaka, Masao // American Surgeon;May2001, Vol. 67 Issue 5, p400 

    Intraductal papillary-mucinous tumor of the pancreas is a spectrum of conditions ranging from benign to malignant, and very few papers have referred to the natural history of this disease. In this communication the indicators of malignancy were examined from a viewpoint of natural history....

  • Gas-chromatography mass-spectrometry determination of phthalic acid in human urine as a biomarker of folpet exposure. Berthet, Aurélie; Berode, Michèle; Bouchard, Michèle // Analytical & Bioanalytical Chemistry;Jun2011, Vol. 400 Issue 2, p493 

    gricultural workers are exposed to folpet, but biomonitoring data are limited. Phthalimide (PI), phthalamic acid (PAA), and phthalic acid (PA) are the ring metabolites of this fungicide according to animal studies, but they have not yet been measured in human urine as metabolites of folpet, only...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics